Duorui pharmaceutical: it plans to invest 5.6 million yuan to establish a holding subsidiary, hairuidi pharmaceutical

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

Pony.ai’s Robotaxi Revenue Rises 691% as Overseas Deployment Pipeline Tops 4,000 Vehicles

Pony.ai reported a sharp acceleration in Robotaxi revenue in the second quarter of 2026, while outlining planned and potential overseas deployments exceeding 4,000 vehicles—signalling the company’s push to turn its China operating experience into a broader international business.

ByteDance’s Proposed US$20 Billion Offshore Loan Draws More Than US$30 Billion of Demand

ByteDance (字节跳动) has drawn more than US$30 billion of demand for a proposed syndicated loan that could become its largest offshore borrowing, Bloomberg reported on Aug. 19, underscoring lenders’ appetite to finance the TikTok owner’s expanding artificial-intelligence infrastructure plans.

Himalaya Turns to Hong Kong for IPO

On September 14, after withdrawing the IPO application on US SEC, China's online audio platform Himalaya submitted an IPO prospectus to the Hong Kong Stock Exchange. The underwriters are Goldman Sachs, Morgan Stanley and CICC.